RhumbLine Advisers
OVID icon

RhumbLine Advisers’s Ovid Therapeutics OVID Stock Holding History

RhumbLine Advisers’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$458K Buy
+170,139
New +$439K ﹤0.01% 2832
2025
Q2 		– Sell
-80,917
Closed -$25.2K – 4229
2025
Q1 		$25.2K Sell
80,917
-3,161
-4% -$1.94K ﹤0.01% 3705
2024
Q4 		$78.5K Buy
84,078
+15,355
+22% +$17.2K ﹤0.01% 3543
2024
Q3 		$81.1K Sell
68,723
-1,010
-1% -$1.05K ﹤0.01% 3571
2024
Q2 		$53.6K Sell
69,733
-12,851
-16% -$35.8K ﹤0.01% 3663
2024
Q1 		$252K Buy
82,584
+2,918
+4% +$9.76K ﹤0.01% 3066
2023
Q4 		$257K Sell
79,666
-3,125
-4% -$10.7K ﹤0.01% 3058
2023
Q3 		$318K Buy
82,791
+4,023
+5% +$14.5K ﹤0.01% 2900
2023
Q2 		$258K Buy
+78,768
New +$267K ﹤0.01% 3099
2021
Q2 		– Sell
-48,990
Closed -$197K – 3077
2021
Q1 		$197K Sell
48,990
-680
-1% -$2.26K ﹤0.01% 2835
2020
Q4 		$115K Buy
49,670
+3,390
+7% +$15.8K ﹤0.01% 2952
2020
Q3 		$266K Sell
46,280
-1,945
-4% -$13K ﹤0.01% 2566
2020
Q2 		$355K Buy
+48,225
New +$226K ﹤0.01% 2491
2019
Q2 		– Sell
-17,010
Closed -$30K – 3000
2019
Q1 		$30K Buy
17,010
+459
+3% +$1.15K ﹤0.01% 2930
2018
Q4 		$40K Buy
16,551
+5,310
+47% +$24.2K ﹤0.01% 2956
2018
Q3 		$64K Sell
11,241
-575
-5% -$4.36K ﹤0.01% 2899
2018
Q2 		$92K Buy
+11,816
New +$101K ﹤0.01% 2879

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

RhumbLine Advisers's OVID Position: Q2 2026 in Review

RhumbLine Advisers opened a new position in Ovid Therapeutics (OVID) in Q2 2026: 170,139 shares worth $458K. The stake represents ﹤0.01% of the portfolio and ranks #2832 among its holdings. This is a return to the name: RhumbLine Advisers previously reported a position in OVID as recently as Q1 2025.

RhumbLine Advisers first reported a position in OVID in Q2 2018 and has held it in 17 quarters since. 130 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • RhumbLine Advisers held 170,139 shares of Ovid Therapeutics worth $458K as of Q2 2026.
  • Ovid Therapeutics was a new RhumbLine Advisers position in Q2 2026.
  • Ovid Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2832 holding.
  • RhumbLine Advisers first reported a position in Ovid Therapeutics in Q2 2018 and has held it in 17 quarters since.
  • 130 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.